1.Dong H, Qian Z, Zhang L, Chen Y, Ren Z, Ji Q. Genomic and transcriptome profiling identified both human and HBV genetic variations and their interactions in Chinese hepatocellular carcinoma. Genom Data. 2015;6:1.
2.Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol. 2013;19:9377–82.
3.Gordon SC, Lamerato LE, Rupp LB, Li J, Holmberg SD, Moorman AC, et al. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clinical Gastroenterology & Hepatology. 2014;12:885–93.
4.Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, et al. Original article: Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. Gut. 2015;64:820.
5.Giannini EG, Savarino V, Risso D, Nolfo MAD, Poggio PD, Benvegnù L, et al. Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study. Liver Int. 2011;31:192–6.
6.Naqvi AR, Seal A, Shango J, Brambila MF, Martinez G, Chapa G, et al. Herpesvirus-encoded microRNAs detected in human gingiva alter host cell transcriptome and regulate viral infection. Biochim Biophys Acta. 2018;1861.
7.Du J, Zhang P, Gan M, Zhao X, Xu Y, Li Q, et al. MicroRNA–204–5p regulates 3T3-L1 preadipocyte proliferation, apoptosis and differentiation. Gene. 2018;668:1–7.
8.Dasgupta P, Kulkarni P, Majid S, Varahram S, Hashimoto Y, Bhat NS, et al. MicroRNA–203 inhibits long noncoding RNA HOTAIR and regulates tumorigenesis through epithelial-to-mesenchymal transition pathway in renal cell carcinoma. Mol Cancer Ther. 2018;17:molcanther.0925.2017.
9.Tan Y, Lin B, Ye Y, Wen D, Chen L, Zhou X. Differential expression of serum microRNAs in cirrhosis that evolve into hepatocellular carcinoma related to hepatitis B virus. Oncol Rep. 2015;33:2863.
10.Riazalhosseini B, Mohamed Z, Apalasamy YD, Eng HS, Mohamed R. Association between microRNA–196A2 and microRNA–146A polymorphisms and progression to cirrhosis and hepatocellular carcinoma in patients with viral hepatitis B. Pharmacogenetics & Genomics. 2016;26:74–9.
11.Xie Y, Yao Q, Butt AM, Guo J, Tian Z, Bao X, et al. Expression profiling of serum microRNA–101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer Biol Ther. 2014;15:1248–55.
12.Yang Y, Zhang J, Xia T, Li G, Tian T, Wang M, et al. MicroRNA–210 promotes cancer angiogenesis by targeting fibroblast growth factor receptor-like 1 in hepatocellular carcinoma. Oncol Rep. 2016.
13.Xia T, Yang Y, Li G, Zhang J, Yang Y, Wei Y, et al. P0233: Microrna–210 enhances tumor angiogenesis by targeting FGFRL1 in hepatocellular carcinoma. J Hepatol. 2015;62:S394-S.
14.Walsh MJ. Investigating the biochemical progression of liver disease through fibrosis, cirrhosis, dysplasia, and hepatocellular carcinoma using Fourier transform infrared spectroscopic imaging. Biomedical Vibrational Spectroscopy VI: Advances in Research and Industry; 2014. p.89390J-J–7.
15.Amponsah PS, Fan P, Bauer N, Zhao Z, Gladkich J, Fellenberg J, et al. microRNA–210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer. Cancer Lett. 2017;388:107–17.
16.Eminaga O, Fries J, Woetzel F, Warnecke-Eberz U, Neiss S, Heitmann M, et al. Enhanced overexpression of hypoxia-related miRNA–210 in primary tumor of metastatic prostate cancer. J Clin Oncol. 2016;34:166-.
17.Ke HL, Li WM, Lin HH, Hsu WC, Hsu YL, Chang LL, et al. Hypoxia-regulated MicroRNA–210 Overexpression is Associated with Tumor Development and Progression in Upper Tract Urothelial Carcinoma. Int J Med Sci. 2017;14:578–84.
18.Greither T, Würl P, Grochola L, Bond G, Bache M, Kappler M, et al. Expression of microRNA 210 associates with poor survival and age of tumor onset of soft‐tissue sarcoma patients. Int J Cancer. 2015;130:1230–5.
19.Zhan M, Li Y, Hu B, He X, Huang J, Zhao Y, et al. Serum microRNA–210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol. 2014;25:1279–87.e1.
20.Sharma S, Zhou X, Wong D, Lichtenstein A. The early growth response 3 gene (egr3), located at 8p21, is a possible tumor suppressor in head and neck cancer (HNC). Cancer Res. 2007;67:3663-.
21.Pio R, Jia Z, Baron VT, Mercola D. Early growth response 3 (Egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer. Plos One. 2013;8:e54096.
22.Zhang S, Xia C, Xu C, Liu J, Zhu H, Yang Y, et al. Early growth response 3 inhibits growth of hepatocellular carcinoma cells via upregulation of Fas ligand. Int J Oncol. 2017;50.